The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The potential role of anti-hemojuvelin agents for managing anemia in myelofibrosis
In this video, Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the potential role of DISC-0974 and other anti-hemojuvelin agents for the management of myelofibrosis (MF)-associated anemia, highlighting that these drugs may help to address the unmet need of patients with MF and anemia who do not respond to currently available therapies. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
